Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy

Table 2 Univariate analysis to identify risk factors that contributed to a worsening Child-Pugh scores following radiofrequency ablation treatment (n = 123)

Variable	HR	95%CI	P-value
Gender (female vs male)	1.93	0.83-4.47	0.128
Age (yr) (< 70 vs≥ 70)	1.05	0.45-2.44	0.906
CP class (B vs A)	5.03	2.17-11.7	0.000
Size of tumor (mm) (≥ 20 vs < 20)	2.01	0.84-4.81	0.116
Number of tumors (≥ 2 vs 1)	1.47	0.62-3.47	0.379
Total bilirubin (mg/dL) (≥ 1.0 vs < 1.0)	3.48	1.35-8.99	0.010
Albumin (g/dL) (< 3.5 vs≥ 3.5)	8.52	3.12-23.2	0.000
Prothrombin time (< 80% vs≥ 80%)	2.66	1.14-6.23	0.024
Platelet count (104/μL) (< 10 vs≥ 10)	5.04	1.86-13.7	0.001
AST (IU/L) (≥ 40 vs < 40)	7.06	1.57-31.8	0.011
ALT (IU/L) (≥ 35 vs < 35)	4.01	1.32-12.2	0.015
Prior TACE vs no TACE	1.05	0.24-4.48	0.952
Frequency of RFA treatments for recurrent HCC (≥ 2 vs < 2)	1.51	0.64-3.53	0.344

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TACE: Transarterial chemoembolization; CP: Child-Pugh; RFA: Radiofrequency ablation; HCC: Hepatocellular carcinoma.